Expression of Fas receptor and soluble Fas ligand (sFasL) concentration in acute leukemias;Ocena ekspresji receptora Fas oraz stçżenie rozpuszczalnego ligandu Fas (sFasL) w ostrych białaczkach

Polskie Archiwum Medycyny Wewnetrznej

Volumn 108, Issue 3, 2002, Pages 873-878

  Urbaniak Kujda, Donata ^a   Jaźwiec, Bozena ^a   Tomaszewska Toporska, Beata ^a   Wołowiec, Dariusz ^a   Kapelko Słowik, Katarzyna ^a   Kuliczkowski, Kazimierz ^a  

^a Klinika Hematologii I Chorob R   (Poland)

Author keywords

Acute leukemia; Fas; sFasL

Indexed keywords

FAS ANTIGEN; FAS LIGAND; FASLG PROTEIN, HUMAN; MEMBRANE PROTEIN; TUMOR MARKER;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLAST CELL CRISIS; BLOOD; BONE MARROW CELL; CASE CONTROL STUDY; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD95; BLAST CRISIS; BONE MARROW CELLS; CASE-CONTROL STUDIES; FAS LIGAND PROTEIN; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0036769525     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Friesen C., Fulda S., Debatin K.M.: Deficient activation of the CD95 (Apo-1/Fas) system in drug-resistant cells. Leukemia, 1997, 11, 1833.
2. De Maria R., Testa U., Luchetti L: Apoptotic role of Fas/Fas ligand system in the regulation of erythropoiesis. Blood, 1999, 93, 796.
3. Findley HW., Zhou M.: The clinical significance of Fas expression in leukemia: questions and controversies. Leukemia, 1999, 13, 147.
4. Perzova R., Loughran T.P.: Constitutive expression of Fas ligand in large granular lymphocyte leukemia. Br. J. Haematol., 1997, 97, 123.
5. Buzyn A., Petit F. Ostankovitch M.: Membrane-bound Fas (Apo-1/CD95) ligand on leukemic cells: a mechanism of tumor immune escape in leukemia patients. Blood, 1999, 94, 3135.
6. Tanaka M., Itai T., Adachi M.: Down regulation of Fas ligand by shedding. Nat. Med., 1998, 4 (1), 31.
7. Whiteside T.L., Rabinowich H.: The role of Fas/ /FasL in immunosupression induced by human tumors. Cancer Immunol. Immunother., 1998, 46, 175.
8. Gupta P., Niehans G.A., LeRoy S.C.: Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anaemia and predicts survival. Leukemia, 1999, 13, 44.
9. McGahon A.J., Costa Pereira A.P., Daly L.: Chemotherapeutic drug-induced apoptosis in human leukemic cells is independent of the Fas (Apo-1/ /CD95) receptor/ligand system. Br. J. Haematol., 1998, 101, 539.
10. Villunger A., Egle A., Kos M.: Drug induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signalling in human T-acute lymphatic leukemia cells. Cancer Res.,1997, 57, 3331.
11. Das H., Imoto S., Murayama T.: Levels of soluble FasL and FasL gene expression during the development of graft-versus-host disease in DLT-treated patients. Br. J. Haematol., 1999, 104, 795.
12. Tanaka M., Suda T., Haze K.: Fas ligand in human serum. Nat. Med., 1996, 2 (3), 317.
13. Walker P.R., Saas P., Dietrich P.Y.: Role of Fas ligand (CD95) in immune escape. J. Immunol., 1997, 158, 4521.
14. Min Y.H., Lee S., Lee J.W.: Expression of Fas antigen in acute myeloid leukemia is associated with therapeutic response to chemotherapy. Br. J. Haematol., 1996, 93, 928.
15. Baryshinikov A., Polosukhina E.R., Tupitsin N.N.: CD95 (Fas/Apo-1) is new prognostic marker of blast cells of acute lymphoblastic leukaemia patients. Adv. Exp. Med. Biol., 1999, 457, 251.
16. Iijima N., Miyamura K., Itou T.: Functional expression of Fas (CD95) in acute myeloid leukemia cells in the context of CD34 and CD38 expression: possible correlation with sensitivity to chemotherapy. Blood, 1997, 90, 4901.
17. Konrada Y., Sakurai M.: Fas receptor (CD95)-mediated apoptosis in leukemic cells. Leuk. Lymphoma, 1997, 25, 9.
18. Li Q., Tsuruda K., Sugahara K.: Qualitative and quantitative characterization of Fas (CD95) expression and its role in primary human acute leukemia cells. Leuk. Res., 2000, 24, 437.
19. Bruserud O., Ulvestad E.: Soluble Fas/Apo-1 (CD95) levels during T cell activation in the presence of acute myelogenous leukemia accessory cells; contributions from local release and variations in systemic levels. Cancer Immunol. Immunother., 2000, 49, 377.
20. Lickliter J.D., Kratzke R.A., Nguyen P.L.: Fas ligand is highly expressed in acute leukemia and during the transformation of chronic myeloid leukemia to blast crisis. Exp. Hematol., 1999, 27, 1519.
21. Suda T., Hashimoto H., Tanaka M.: Membrane Fas ligand kills human peripheral blond T lymphocytes, and soluble Fas ligand blocks killing. J. Exp. Med., 1997, 186, 2045.
22. Sugahara K., Yamada Y., Hiragata Y.: Soluble and membrane isoforms of Fas/CD95 in fresh adult T-cell leukemia (ATL) cells and ATL-cell lines. Int. J. Cancer, 1997, 72, 128.
23. Walker P., Saas P., Dietrich P.Y.: Tumor expression of Fas ligand (CD95L) and the consequences. Curr. Opin. Immunol., 1998, 10, 564.